Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation

Moser Christian, Pohl Gudrun, Haslinger Isabella, Knapp Sylvia, Rowczenio Dorota, Russel Tonia, Lachmann Helen J., Lang Ursula, Kovarik Josef

Research output: Journal article (peer-reviewed)Journal article

111 Citations (Scopus)


Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent episodes of fever and inflammation. The most severe complication of FMF is the development of AA amyloidosis, which can be life threatening. The only current effective treatment for FMF is colchicine. Regular prophylactic treatment with colchicine at a dose of 1–2 mg daily prevents or substantially reduces the clinical manifestations of FMF in at least 90% of cases. However, ∼10% of patients are reported to be resistant or non-responsive to colchicine and in these cases there is no consensus as to which second line agents should be used. We describe the first case, to our knowledge, of a patient with FMF and end-stage renal failure due to AA amyloidosis, successfully treated with IL-1 receptor blockade. Our data suggest that the IL-1 receptor antagonist Anakinra (Kineret®; r-metHuIL-1 ra) may represent a safe and effective therapy for the treatment of colchicine-resistant FMF, in patients r
Original languageEnglish
Pages (from-to)676-678
Number of pages3
JournalNephrology Dialysis Transplantation
Issue number2
Publication statusPublished - Feb 2009
Externally publishedYes


  • FAMILIAL Mediterranean fever
  • KIDNEY transplantation
  • HEALTH outcome assessment
  • DISEASE complications
  • Interleukin-1 receptor antagonist
  • Familial Mediterranean fever
  • Colchicine
  • Anakinra

ASJC Scopus subject areas

  • Nephrology
  • Transplantation


Dive into the research topics of 'Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation'. Together they form a unique fingerprint.

Cite this